Acute Lymphoblastic Leukemia
High levels of CAR-T cell expansion in vivo and high pretreatment disease burden appeared to increase the likelihood that a neurotoxic event may occur following CAR-T administration.
The efficacy of nelarabine among newly diagnosed patients with T-cell ALL has not been fully explored.
The FDA based its approval on results of the single-arm phase 2 JULIET clinical trial.
Previous studies demonstrated that inotuzumab ozogamicin significantly improves clinical outcomes vs standard of care chemotherapy, but impact on QoL was unknown.
1. Patients with a higher disease burden of acute lymphoblastic leukemia (ALL) treated with CD19-specific chimeric antigen receptor (CAR) T cell therapy experienced greater incidences of cytotoxic release syndrome and neurotoxicity compared to low disease burden patients. 2. Patients with high disease burden had shorter overall survival times compared to low disease burden patients. Evidence 
Researchers evaluated the outcomes of older vs younger patients with R/R ALL treated with InO or investigators' choice of chemotherapy.
Inherited TP53 variants may be crucial for acute lymphoblastic leukemia (ALL) leukemogenesis and response to treatment, according to a study published in the Journal of Clinical Oncology.1
Researchers assessed the efficacy of dasatinib — a TKI that is significantly more potent than imatinib and is active even in the setting of imatinib resistance — in this patient population.
Based on findings from previous studies (COG AALL0031 and EsPhALL 2004-2009), researchers are assessing the association of continuous imatinib plus chemotherapy with the reduced need for HSCT.
Elias Jabbour, MD, discusses the latest developments in the treatment of acute and chronic leukemia from the ASH 2017 meeting.
Eleven patients had a complete response: 10 had complete cytogenic remission, 8 were negative by flow cytometry, 6 had undetectable BCR-ABL. Three patients did not respond.
For a meta-analysis, researchers evaluated outcomes data from 9 studies consisting of 6762 patients with an acute leukemia to determine whether HSCT is superior to UCBT.
Previous studies demonstrated that MRD and genetic abnormalities are critical predictors of relapse in ALL, but current algorithms view MRD and genetics as independent variables when assessing risk.
The FDA granted approval to inotuzumab ozogamicin for the treatment of adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Enthusiasm for the CAR T cell approach may redirect rather than augment other possibly safer, more effective, evolutionarily informed approaches to cancer therapy.
Early response-based treatment intensification with allo-SCT improved OS among adult patients with early thymic precursor T cell ALL.
Long-term cure of ALL is achieved by 80% of children with the disease, but questions remain regarding how to balance morbidity and HRQoL related to treatment.
Leukemia remains the most common cancer type for children aged 14 years or younger, worldwide, representing a third of cases for children younger than 10 years.
The addition of rituximab to chemotherapy may benefit patients being treated for acute lymphoblastic leukemia (ALL).
This fact sheet provides patients with acute lymphocytic leukemia strategies for coping, treatment options, and more.
Patients with ALL treated with the monoclonal antibody inotuzumab ozogamicin were more likely to proceed to stem cell transplantation.
Ponatinib resulted in durable responses after 4 years in heavily pretreated patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.
Young children born by pre-labor cesarean delivery may be at an increased risk of childhood acute lymphoblastic leukemia (ALL).
Results of TOWER study evaluating blinatumomab in acute lymphoblastic leukemia (ALL) showed that the primary endpoint was met.
An intensive pediatric-like acute lymphoblastic leukemia (ALL) treatment protocol was associated with a good response rate.
Adding rituximab to the pediatric-inspired GRAALL protocol improved event-free survival in acute lymphoblastic leukemia.
The change in drug sensitivity by tumor cells resistant to Notch or BET inhibitors results from selective use of individual enhancers.
Intravenous pegylated Escherichia coli asparaginase (PEG-asparaginase) was not more toxic in children with acute lymphoblastic leukemia (ALL).
The FDA has granted breakthrough therapy designation to inotuzumab ozogamicin for treatment of acute lymphoblastic leukemia (ALL).
About one-third of adult patients with B-precursor acute lymphoblastic leukemia had a survival of at least 30 months when administered blinatumomab.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC